Clinical trials: Alzheimer Blood Biomarkers
Alzheimer Disease, Alzheimer Disease, Early Onset
A Biomarker Database to Investigate Blood-Based and Digital Biomarkers in Participants Screened for Alzheimer's Disease (Bio-Hermes)
The purpose of this study (Bio-Hermes) is to develop a blood, digital, and brain amyloid PET scan biomarker database that can be used to determine whether a meaningful relationship exists between digital tests, blood…
- Conditions
- Alzheimer Disease, Alzheimer Disease, Early Onset, Mild Cognitive Impairment, Memory Loss
- Trial name
- NCT04733989
- Testing
- Biomarker Data Collection
- Where
- 16 sites in United States
- Volunteers
- 1,002 people
- Sponsor
- GAP Innovations, PBC
Alzheimer Disease
Study on Novel Peripheral Blood Diagnostic Biomarkers for MCI Due to Alzheimer's Disease
The prevalence of Mild Cognitive Impairment (MCI) is about 15%-17%. 10%-15% of MCI progresses to Alzheimer's disease (AD) every year. The annual incidence of MCI in the normal elderly is about 1%.
- Trial name
- Precision1000 (NCT04509271)
- Testing
- MicRNAs battery kits
- Where
- China
- Volunteers
- 1,300 people, healthy volunteers welcome
- Sponsor
- Shanghai Mental Health Center
Alzheimer Disease, Cognitive Dysfunction, Cognitive Disorder
DIV-AD BARCELONA: Alzheimer's Blood-Based Biomakers for a Diverse Community
The DIV-AD study aims to find out whether levels of Alzheimer's disease markers in blood differ among the main ethnical groups living in central Barcelona.
- Conditions
- Alzheimer Disease, Cognitive Dysfunction, Cognitive Disorder, Dementia, Neurodegenerative Disease
- Trial name
- DIV-AD (NCT07521722)
- Where
- Spain
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Barcelonabeta Brain Research Center, Pasqual Maragall Foundation
Alzheimer's Disease (AD), Neurodegenerative Disease
A Biomarker-chip Assay in Preserved Red Blood Cells for the Diagnosis of Alzheimer's Disease
The ADCHIP study (ST0067) is a non-interventional, monocentric, prospective study conducted by Amoneta Diagnostics and the Leenaards Memory Center (Lausanne, Switzerland).
- Conditions
- Alzheimer's Disease (AD), Neurodegenerative Disease, Dementia, Frontotemporal Dementia (FTD)
- Trial name
- ADCHIP (NCT07307872)
- Where
- Switzerland
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Amoneta Diagnostics SAS
Alzheimer Disease, Dementia
Sex-specific Risk Factors and Trajectories of Blood Biomarkers for Alzheimer's Disease and Related Dementias
Blood-based ADRD biomarkers show tremendous promise as a non-invasive method to predict and diagnose ADRD. We will measure changes in these biomarkers to determine whether their ability to predict ADRD differs by sex or by other…
- Conditions
- Alzheimer Disease, Dementia, Cognitive Dysfunction
- Trial name
- NCT07224139
- Where
- 5 sites in United States, Australia
- Volunteers
- 13,435 people, healthy volunteers welcome
- Sponsor
- Anne Murray
Alzheimer Disease
ADDIA Chronobiological Study
The present single center clinical chronobiological study on 24 subjects (12 patients with mild to moderate form of Alzheimer's disease and 12 Healthy subjects) aims at characterizing the ADDIA biomarkers: a) blood cell-based…
- Trial name
- NCT02973971
- Testing
- volumeric MRI
- Where
- France
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Amoneta Diagnostics SAS
Alzheimer Disease
Alzheimer Biomarkers on CSF of Elderly Patients Undergoing Surgery
Dementia is a syndrome characterized by cognitive and behavioral impairment in older adults, which usually manifests as memory loss, communication difficulties or changes in mood.
- Trial name
- NCT03977025
- Testing
- Lumbar punction
- Where
- Chile
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Chile
Dementia of Alzheimer Type, Alzheimer Disease
Prevalence of Alzheimer's Disease Pathology in the Community
The goal of this observational study is to (I) study the proportion of people with Alzheimer's disease pathology in a large Norwegian population-based cohort of people aged 70 years or older and to (II) study longitudinal changes…
- Conditions
- Dementia of Alzheimer Type, Alzheimer Disease, Mild Cognitive Impairment, Pathology
- Trial name
- HUNT4AD (NCT06719453)
- Volunteers
- 9,663 people, healthy volunteers welcome
- Sponsor
- Helse Stavanger HF
Dementia Alzheimers
Blood-based Biomarkers for Diagnosis of Alzheimer's
Alzheimer's disease (AD) may currently be diagnosed using molecular biomarkers in cerebrospinal fluid (CSF) and/or positron emission tomography (PET).
- Trial name
- NCT05187819
- Testing
- predictive value of a blood test
- Where
- Norway
- Volunteers
- 300 people
- Sponsor
- Helse Stavanger HF
Elderly, Alzheimer Disease
Effects of 3-Month Melatonin Treatment on Regional Cerebellar Structure and Blood Biomarkers in Alzheimer's Disease Spectrum
The goal of this clinical trial is to explore and verify the preventive effects of melatonin on the progression of Alzheimer's disease.
- Conditions
- Elderly, Alzheimer Disease, Melatonin, Cognitive Decline
- Trial name
- NCT06756828
- Testing
- Melatonin, Cognitive behavioral therapy group for insomnia
- Volunteers
- 40 people
- Sponsor
- Saint Vincent's Hospital, Korea
Alzheimer Disease, Biomarkers / Blood
Blood Biomarkers for Early and Accurate Diagnosis of Alzheimer's Disease in Primary Care
Alzheimer's disease is a degenerative condition affecting the brain and is the most common form of dementia in older adults. Dementia is currently a major healthcare issue in the UK, affecting approximately a million people.
- Conditions
- Alzheimer Disease, Biomarkers / Blood, Biomarker in Early Diagnosis, Mild Cognitive Impairment (MCI)
- Trial name
- BEAD-PC (NCT07401849)
- Volunteers
- 1,000 people
- Sponsor
- Imperial College London
Alzheimer Disease
Davos Alzheimer's Collaborative Study: Sequential Administration of Digital Testing To Screen For Cognitive Impairment Followed By Blood Based Biomarkers To Assist With Timely Detection And Accurate Diagnosis Of Alzheimer's Disease
The purpose of this study is to investigate how we can detect Alzheimer's disease early by using an online memory test and a simple blood test.
- Trial name
- DAC (NCT05379348)
- Testing
- Cognitive Assessment
- Where
- United States
- Volunteers
- 1,423 people, healthy volunteers welcome
- Sponsor
- AdventHealth Translational Research Institute
Alzheimer Disease
Evaluation of a Finger Prick Collection Method for Measuring Alzheimer's Disease Blood Biomarkers
This is an observational study that will collect blood from a finger prick (Capitainer SEP10 single channel device) and assess the accuracy of pTau-217 testing in comparison to previously collected venous blood samples from the…
- Trial name
- eDROP-AD (NCT07187921)
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Banner Health
Subjective Cognitive Decline (SCD)
PENSA+: Extended Follow-up of a Multimodal Lifestyle Intervention to Prevent Cognitive Decline in APOE-ε4 Carriers
PENSA+ is a 5-year follow-up study of participants who previously completed the PENSA clinical trial (NCT03978052), which evaluated an intensive multimodal lifestyle intervention, with or without epigallocatechin gallate (EGCG)…
- Trial name
- PENSA+ (NCT07730671)
- Where
- Spain
- Volunteers
- 121 people
- Sponsor
- Barcelonabeta Brain Research Center, Pasqual Maragall Foundation
Mild Cognitive Impairment, Alzheimer's Disease
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
Bio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective.
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss
- Trial name
- Bio-Hermes-002 (NCT06584357)
- Testing
- Biomarker Data Collection, MK6240
- Where
- 26 sites in United States, Canada and 1 more
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- GAP Innovations, PBC
Alzheimer's Disease
A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology
The primary purpose of this study is to identify participants with or without symptoms of Alzheimer's Disease (AD) that are at high risk for brain amyloid pathology using blood-based biomarkers.
- Trial name
- NCT06043700
- Testing
- No Intervention
- Where
- 3 sites in United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Eisai Limited
Alzheimer Blood Biomarkers
Diagnostic Performance of Plasma Biomarkers of Alzheimer's Disease Compared With CSF Markers
.The goal of this interventional study is to estimate the diagnostic performance of plasma biomarkers of interest (Aβ40 and Aβ42, P-Tau and NFL), enabling discrimination between patients with and without a pathophysiological AD…
- Trial name
- PLASM-ALZ (NCT06304129)
- Testing
- Blood ponction
- Where
- France
- Volunteers
- 189 people
- Sponsor
- Central Hospital, Nancy, France
Alzheimer Disease, Elderly With Normal Cognition
Blood Microbiota Signature of Alzheimer's Disease
This study aims to validate a difference in blood microbial signature between Alzheimer's patients and control subjects in order to propose potential innovative strategies
- Trial name
- MICMALZ (NCT04841135)
- Testing
- Multiomics quantification, Polysomnography
- Where
- France
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Mild Cognitive Impairment Due to Alzheimer's Disease, Dementia Due to Alzheimer's Disease (Disorder)
Biomarkers of Cognitive Impairment in Blood Cells
The aim of this study is to identify transcriptomic biomarkers in blood cells to diagnose early cognitive impairment. This would allow preventing the development of severe pathologies, such as Alzheimer Disease.
- Trial name
- COGNIMARK (NCT05582941)
- Testing
- No intervention will be performed.
- Where
- Spain
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of the Balearic Islands
Cognitive Decline
Clinical Application and Usability of Blood Biomarkers As Screening Tool in Alzheimer Disease: a Validation Study
Dementia caused by neurodegenerative diseases affects over 50 million people worldwide, Alzheimer's disease (AD) being the most common cause.
- Trial name
- BIOVALID-AD (NCT06699992)
- Testing
- Blood biomarkers quantification
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS